Schedule-at-a-Glance

Schedule-at-a-Glance

■ Social Events & Networking ■ Ceremonies ■ Workshops ■ Panels ■ Plenaries ■ Symposia ■ Exclusive Symposia

UTC	CST (UTC +8) (East Asia)	CEST (UTC +2) (Europe)	BST (UTC +1) (UK)	PDT (UTC-7) (North America)	Saturday 19 June	Sunday 20 June	Monday 21 June	Tuesday 22 June	Wednesday 23 June
05:00	13:00	07:00	06:00	22:00 (DAY-1)				Panel Session 2	Panel Session 6
05:15	13:15	07:15	06:15	22:15 (DAY-1)					
05:30	13:30	07:30	06:30	22:30 (DAY-1)					
05:45	13:45	07:45	06:45	22:45 (DAY-1)					
06:00	14:00	08:00	07:00	23:00 (DAY-1)					
06:15	14:15	08:15	07:15	23:15 (DAY-1)					
06:30	14:30	08:30	07:30	23:30 (DAY-1)					
06:45	14:45	08:45	07:45	23:45 (DAY-1)					
07:00	15:00	09:00	08:00	00:00					
07:15	15:15	09:15	08:15	00:15					
07:30	15:30	09:30	08:30	00:30					Keynote 3
07:45	15:45	09:45	08:45	00:45			Opening Ceremony		
08:00	16:00	10:00	09:00	01:00	Workshops	Workshops	Keynote 1	Panel Session 3	Panel Session 7
08:15	16:15	10:15	09:15	01:15					
08:30	16:30	10:30	09:30	01:30					
08:45	16:45	10:45	09:45	01:45					
09:00	17:00	11:00	10:00	02:00			Plenary 1 Presentation		
09:15	17:15	11:15	10:15	02:15					
09:30	17:30	11:30	10:30	02:30					
09:45	17:45	11:45	10:45	02:45					
10:00	18:00	12:00	11:00	03:00			Plenary 1 Discussion (Part 1)	Exclusive Symposium 3	Exclusive Symposium 4
10:15	18:15	12:15	11:15	03:15					
10:30	18:30	12:30	11:30	03:30					
10:45	18:45	12:45	11:45	03:45					
11:00	19:00	13:00	12:00	04:00					
11:15	19:15	13:15	12:15	04:15					
11:30	19:30	13:30	12:30	04:30					
11:45	19:45	13:45	12:45	04:45					
12:00	20:00	14:00	13:00	05:00	Workshops	Workshops	Panel Session 1	Panel Session 4	Panel Session 8
12:15	20:15	14:15	13:15	05:15					
12:30	20:30	14:30	13:30	05:30					
12:45	20:45	14:45	13:45	05:45					
13:00	21:00	15:00	14:00	06:00					
13:15	21:15	15:15	14:15	06:15					
13:30	21:30	15:30	14:30	06:30					
13:45	21:45	15:45	14:45	06:45					
14:00	22:00	16:00	15:00	07:00				Symposia Session 1	Plenary 3 Presentation
14:15	22:15	16:15	15:15	07:15			Exclusive Symposium 1		
14:30	22:30	16:30	15:30	07:30					
14:45	22:45	16:45	15:45	07:45					
15:00	23:00	17:00	16:00	08:00		Welcome Reception			Plenary 3 Discussion
15:15	23:15	17:15	16:15	08:15				Keynote 2	
15:30	23:30	17:30	16:30	08:30					
15:45	23:45	17:45	16:45	08:45					
16:00	00:00 (DAY+1)	18:00	17:00	09:00	Platform Orientation		Breakout Session	Plenary 2 Presentation	Awards Presentations and Closing Ceremony
16:15	00:15 (DAY+1)	18:15	17:15	09:15					
16:30	00:30 (DAY+1)	18:30	17:30	09:30					
16:45	00:45 (DAY+1)	18:45	17:45	09:45				Plenary 2 Discussion	
17:00	01:00 (DAY+1)	19:00	18:00	10:00	Workshops	Workshops			
17:15	01:15 (DAY+1)	19:15	18:15	10:15					
17:30	01:30 (DAY+1)	19:30	18:30	10:30			Opening Ceremony (rebroadcast)		
17:45	01:45 (DAY+1)	19:45	18:45	10:45					
18:00	02:00 (DAY+1)	20:00	19:00	011:00			Keynote 1 (rebroadcast)	Catch-Up & Connect	Panel Session 9
18:15	02:15 (DAY+1)	20:15	19:15	11:15					
18:30	02:30 (DAY+1)	20:30	19:30	11:30					
18:45	02:45 (DAY+1)	20:45	19:45	11:45			Plenary 1 Presentation (rebroadcast)		
19:00	03:00 (DAY+1)	21:00	20:00	12:00			Plenary 1 Discussion (Part 2)		Symposia Session 3
19:15	03:15 (DAY+1)	21:15	20:15	12:15					
19:30	03:30 (DAY+1)	21:30	20:30	12:30					
19:45	03:45 (DAY+1)	21:45	20:45	12:45					
20:00	04:00 (DAY+1)	22:00	21:00	13:00					
20:15	04:15 (DAY+1)	22:15	21:15	13:15					
20:30	04:30 (DAY+1)	22:30	21:30	13:30					
20:45	04:45 (DAY+1)	22:45	21:45	13:45					
21:00	05:00 (DAY+1)	23:00	22:00	14:00	Workshops				
21:15	05:15 (DAY+1)	23:15	22:15	14:15				Panel Session 5	
21:30	05:30 (DAY+1)	23:30	22:30	14:30					
21:45	05:45 (DAY+1)	23:45	22:45	14:45					
22:00	06:00 (DAY+1)	00:00 (DAY+1)	23:00	15:00					Panel Session 10
22:15	06:15 (DAY+1)	00:15 (DAY+1)	23:15	15:15					
22:30	06:30 (DAY+1)	00:30 (DAY+1)	23:30	15:30					
22:45	06:45 (DAY+1)	00:45 (DAY+1)	23:45	15:45					
23:00	07:00 (DAY+1)	01:00 (DAY+1)	00:00 (DAY+1)	16:00					
23:15	07:15 (DAY+1)	01:15 (DAY+1)	00:15 (DAY+1)	16:15					
23:30	07:30 (DAY+1)	01:30 (DAY+1)	00:30 (DAY+1)	16:30					Closing Ceremony (rebroadcast)
23:45	07:45 (DAY+1)	01:45 (DAY+1)	00:45 (DAY+1)	16:45					

Program
Agenda

Program Agenda

Saturday, June 19, 2021

08:00 – 11:00 (UTC)	**Workshops** • **WS02** HTA 102: How HB-HTA Impacted by the Pandemic: Role, Steps of an Evaluation-Rapid Assessment and Implementation of its Recommendation • **WS03** Advanced Workshop in Information Retrieval: The NICE Information Services Team, Innovative Automation Tools, and Unlimited Possibilities! • **WS06** Values in Doing Assessments of Healthcare Technologies
11:00 – 12:00 (UTC)	**Break**
12:00 – 15:00 (UTC)	**Workshops** • **WS02** HTA 102: How HB-HTA Impacted by the Pandemic: Role, Steps of an Evaluation-Rapid Assessment and Implementation of its Recommendation • **WS03** Advanced Workshop in Information Retrieval: The NICE Information Services Team, Innovative Automation Tools, and Unlimited Possibilities! • **WS07** Horizon Scanning of New and Emerging Health Technologies (Medicines, Devices, Diagnostics and Digital) for HTA Stakeholders
16:00 – 17:00 (UTC)	**Virtual Meeting Platform Orientation**
17:00 – 20:00 (UTC)	**Workshops** • **WS08** A Hands-On Workshop on the Theory and Practice of Assessing the Impact of Health Technology Assessment • **WS09** Environmental Sustainability in HTA: Methods and Outputs Workshop • **WS10** Introduction to Ethics in Health Technology Assessment
20:00 – 21:00 (UTC)	**Break**
21:00 – 00:00 (UTC)	**Workshops** • **WS11** HTA 101 - Introduction to Health Technology Assessment

Sunday, June 20, 2021

08:00 – 11:00 (UTC)	**Workshops** • **WS04** A Comprehensive Evaluation of High-Tech Medical Equipment—Methods and Practices • **WS05** Medical Devices Interest Group Workshop - Case Studies in Health Technology Assessment and Value Based Health Care • **WS12** An Introduction to Early Health Technology Assessment • **WS13** Simplifying Horizon Scanning with the Use of Digital Solutions
11:00 – 12:00 (UTC)	**Break**
12:00 – 15:00 (UTC)	**Workshops** • **WS14** Conceptualizing Patient-Involvement in Countries with Expanding Healthcare Coverage: Identifying Opportunities in Low- and Middle-Income Countries (LMICs) • **WS15** The Use of Evidence-Informed Deliberative Processes for Health Technology Assessment in Low- and Middle-Income Countries (LMIC)
15:00 – 16:30 (UTC)	**Welcome Reception**
17:00 – 20:00 (UTC)	**Workshops** • **WS16** Co-creating Value Assessment Frameworks for Comprehensive Genomic Profiling (CGP) and Next Generation Sequencing (NGS) Technologies • **WS17** Generating and Using Real World Evidence for Health Technology Assessment • **WS18** Providing Intelligence to Support an Accelerated Innovation Pathway: A UK COVID-19 Story • **WS19** Putting Patients at the Heart: Resources and Good Practice for Patient Involvement in Health Technology Assessment

Monday, June 21, 2021

07:45 – 08:45 (UTC)	**Welcome Ceremony** **Keynote Address 1,** Dr June Raine CBE, Chief Executive, Medicines and Healthcare Products Regulatory Agency
09:00 – 10:30 (UTC)	**Plenary 1** Evidence for HTA: Innovative Methods for Challenging Times
10:30 – 12:00 (UTC)	**Break**
12:00 – 15:00 (UTC)	**Panel Session 1** • **PN02** HTA: Friend or Foe in the Quest for Effective Antimicrobials? • **PN03** Involving Patients in Health Technology Assessment in Low and Middle-Income Countries (LMICs): Making the Ends Meet • **PN04** Necessity is the Mother of Invention: How Hospital HTA Centers Responded to the Pandemic • **PN05** Patient Participation at The Organizational Level in Health Technology Assessment
13:15 – 14:30 (UTC)	**Break**
14:30 – 15:45 (UTC)	**Symposium** Tumor Agnostic Medicines for Rare Genomic Alterations: Meeting the HTA and Market Access Challenges (Bayer AG)
16:00 – 16:30 (UTC)	**Themed Breakout Session**
17:45 – 18:45 (UTC)	**Welcome Ceremony** **Keynote Address 1**, Dr June Raine CBE, Chief Executive, Medicines and Healthcare Products Regulatory Agency
19:00 – 20:30 (UTC)	**Plenary 1** Evidence for HTA: Innovative Methods for Challenging Times

Tuesday, June 22, 2021

05:00 – 06:15 (UTC)	**Panel Session 2** • **PN07** Bridging Evidence Gaps in HTA: Building Confidence in Analytical Methods for Combining Results from Randomized and Non-Randomized Studies • **PN08** Digital Health Interventions – Evidence Needed, Methods and Assessment for Policy Decisions • **PN09** Finding the Right HTA Roadmap: How Learnings from Eastern European Countries May Inform HTA Implementation Strategies • **PN10** Health Technology Assessment of Vaccination in Elderly: Application and Implementation Considerations • **PN11** Patients at the Heart of Innovation: Strengthening Patient Voices in HTA Publishing
06:15 – 08:00 (UTC)	**Break**
08:00 – 09:15 (UTC)	**Panel Session 3** • **PN12** Evidence-Informed Priorities and Achieving Universal Health Coverage in Low and Middle-Income Countries • **PN13** Exception or Mainstream? An Assessment of Past, Present and Future Challenges with Managed Access • **PN14** Innovative Patient Involvement During Covid-19: Keeping Patients at the Heart of NICE Guidance Development • **PN15** Making HTA Systems Ready for Reassessment and Disinvestment • **PN16** Methodological and Policy Developments to Support the Use of Non-Randomised Studies in HTA Decision Making • **PN17** Sustainable Health Care, The Capability Approach, And Health Technology Assessment
09:15 – 10:15 (UTC)	**Break**
10:15 – 11:30 (UTC)	**Symposium** Giving Caregivers a Clear Voice (Takeda UK, Ltd)
11:45 – 13:00 (UTC)	**Panel Session 4** • **PN18** Considering and Communicating Uncertainty in HTA: HTAi Global Policy Forum 2021 Findings • **PN19** Deliberative Processes for HTA: Deliberating the Results of The Joint HTAi – ISPOR Task Force • **PN20** Early Engagement with Patients for Enriched Decision-Making and Faster Access to Innovative Therapies: Current Gaps and Possible Solutions • **PN21** Opposing Agendas or Aligned Goals? The Importance of Regulatory Science in HTA
13:00 – 13:45 (UTC)	**Break**

(Tuesday, June 22, 2021 continued)

13:45 – 15:00 (UTC)	**Symposium** Evolving HTA Frameworks to Keep Pace with Cancer Innovation and Accelerate Access for Patients (Janssen) **Symposium** Converging Novel HTA and Access Pathways in Adaptable Healthcare Systems (Novartis) **Symposium** What Role might Outcomes-Based Agreements for Medicines play in future Value-Based Healthcare Systems? (Pfizer UK)
15:30 – 15:45 (UTC)	**Keynote Address 2**, Neil Bertelsen, Patient Advocate
16:00 – 17:30 (UTC)	**Plenary 2** Patients at the Heart of Innovation
17:30 – 19:00 (UTC)	**Catch-Up & Connect**
19:00 – 21:15 (UTC)	**Break**
21:15 – 22:15 (UTC)	**Panel Session 5** • **PN23** Achieving Effective Patient Engagement in Rapid-Cycle Medical Devices HTAs • **PN24** Comprehensive Genomic Profiling (CGP): Can it Ever Bring Enough Value for Routine Clinical Practice? • **PN25** HTA and Clinical Guidelines – Aligning Methods and Objectives for Better Evidence-Informed Decision Making • **PN26** Innovating HTA to Support Novel Interventions for Rare Diseases • **PN27** Not Cost-Effective Even at Zero Price: Understanding and Addressing Challenges around Combination Regimens in Oncology

Wednesday, June 23, 2021

05:00 – 06:15 (UTC)	**Panel Session 6** • **PN28** HTA for Medical Devices: Place and Role in Health System • **PN29** Interconnected Diabetes Technologies & Lower Socio-Economic Status Patient Groups: Understanding Variation in Access & the Role of HTA • **PN30** Problems and Promises of Rapid Video Conference Implementation in Clinical Settings during a Pandemic • **PN31** Real-World Data Collection and Real-World Evidence Generation for Health Technology Assessments • **PN32** Technology Appraisal and Clinical Guideline Development: Should Alignment and Synergy be a Priority for Next Generation HTA?
06:15 – 07:30 (UTC)	**Break**
07:30 – 08:00 (UTC)	**Keynote Address 3,** Melanie Lee, CEO, LifeArc
08:15 – 09:30 (UTC)	**Panel Session 7** • **PN33** Addressing the Issues of the HTA Assessment and Evaluation of Combination Treatments • **PN01** Building Capacity through Multi-Stakeholder Engagement in Assessment and Intervention Methods of Hospital Malnutrition in Selected African Countries • **PN34** Making Room for Disruptive Innovation in the Horizon. Priorities, Agility and Efficiency for All • **PN35** Maximising Population Health While Addressing Inequalities – The Challenge for Decision Makers • **PN36** Measuring and Valuing Health-Related Quality of Life in Children: Innovative Methods to Support Innovative Treatments • **PN37** Transferring Cost-Effectiveness Data across Settings: Findings from the Decide Hub Working Group
09:30 – 10:15 (UTC)	**Break**
10:15 – 11:30	**Symposium** From NYHA to KCCQ: A Novel Approach to Cost-effectiveness Analysis in Heart Failure (the AFFIRM-AHF Case Study) (Vifor Pharma)
11:45 – 13:00	**Panel Session 8** • **PN38** Can Outcomes-Based Managed Entry Agreements Deliver Evidence for Rare Disease Treatments? • **PN39** Health Technology Assessment Impacts on Universal Health Coverage in Selected LMICs: Reviews and Outlooks • **PN40** Health Technology Assessment of COVID-19 Vaccination: An Update of The HTAi Statement • **PN41** Moving Forward Assessing Health Technologies: Strengthening Collaborative Linkages between HTA, TA and Responsible Innovation in Health • PN42 Patient Engagement in Early Dialogues – Experiences, Tools and Resources for HTA Bodies

(Wednesday, June 23, 2021 continued)

13:00 – 14:30	**Break**
14:30 – 16:00 (UTC)	**Plenary Session 3** Innovating HTA to Support Novel Interventions
16:00 – 16:15 (UTC)	**Award Presentations**
16:15 – 16:45 (UTC)	**Closing Ceremony**
16:45 – 18:15 (UTC)	**Break**
18:15 – 19:30 (UTC)	**Panel Session 9** • **PN43** Beyond HTA – Design of a National Audit to Monitor the Adoption of Non-Medicine Technologies in Wales • **PN44** Challenges and Opportunities of Building Value into Development for Innovative Technologies: A Multi-Stakeholder Perspective • **PN46** Evaluation of a Vital Part: Innovative Approaches to Evaluate Patient and Public Involvement in Health Technology Assessment • **PN47** The Use of Deliberative Processes for HTA Decision-Making: Concept, Tools and Applications • **PN48** Valuing Health in a Pandemic: Challenges and Solutions
19:30 – 20:30 (UTC)	**Symposium** How Regulatory Bodies and HTA Agencies can Collaborate to Foster Timely Patient Access to Transformative Innovation (Merck & Co, Inc)
20:30 – 22:00 (UTC)	**Break**
22:00 – 23:15 (UTC)	**Panel Session 10** • **PN49** Cell and Gene Therapies: Ongoing Challenges for HTA, Policy, and Pricing • **PN50** How to Promote Regional Collaboration in HTA on Immunotherapy: Viewpoint from China, Japan, And South Korea • **PN51** Why Can't Health Technology Assessment Always Move This Fast?
23:30 – 00:00 (UTC)	**Closing Ceremony**